Iovance Biotherapeutics Reports Financial Results and
8-K | iXBRL Viewer - IOVANCE Biotherapeutics, Inc.
Year to Date Total Product Revenue and Infusions: Through the end of the third quarter of 2024, $90.4 million in total product revenue has been ...
0001104659-22-086115 | 8-K | iXBRL Viewer
On August 4, 2022, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2022 and ...
... reported its first quarter 2018 financial results and provided a corporate update. ... Iovance Biotherapeutics' website at http://www.iovance.com. About ...
Iovance will host a conference call and live audio webcast to discuss financial results and provide a corporate update today at 4:30 p.m. EDT. To ...
February 22, 2024 - IOVANCE Biotherapeutics, Inc.
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call ... recent Annual Report on Form 10-K and ...
Results of Operations and Financial Condition. On August 6, 2020, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial ...
0001104659-22-114414 | 8-K | iXBRL Viewer
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022. Financial Results and Corporate Updates. First Biologics License Application (BLA) ...
0001104659-21-028227 | 8-K - IOVANCE Biotherapeutics, Inc.
... reported fourth quarter and full year 2020 financial results and corporate updates. Dr. Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance ...
... reported second quarter and first half 2023 financial results and corporate updates. ... statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as ...
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 ...
In addition, these non-GAAP financial measures are among those indicators the company uses as a basis for evaluating operational performance, ...
0001104659-21-062388 | 8-K | iXBRL Viewer
Iovance Biotherapeutics Reports First Quarter 2021. Financial Results and ... reported first quarter 2021 financial results and corporate updates. Maria ...
First Quarter 2019 Financial Results and Provides Corporate Update
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate. Update. May 7, 2019. - First patient dosed in pivotal Cohort 4 ...
0001104659-24-059322 | 8-K - IOVANCE Biotherapeutics, Inc.
... reported first quarter 2024 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance ...
0001104659-23-057722 | 8-K | iXBRL Viewer
Iovance Biotherapeutics Reports First Quarter 2023. Financial Results and ... Iovance reported positive initial results from Cohort 3A of the IOV-COM ...
0001104659-23-088821 | 8-K - IOVANCE Biotherapeutics, Inc.
On August 8, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and ...
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 ...
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides. Corporate Update. February 25, 2020. SAN CARLOS, Calif., ...
Form 10-Q for Iovance Biotherapeutics INC filed 11/07/2024
... statements include the accounts of Iovance Biotherapeutics ... controls could result in a loss of investor confidence in our financial reports.
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results ...
... statements” of Iovance Biotherapeutics, Inc. (hereinafter referred ... recent Annual Report on Form 10-K and Quarterly Reports on Form ...
... reported second quarter and first half 2024 financial results and corporate updates. ... statements” of Iovance Biotherapeutics, Inc. (hereinafter ...
D. Title: Interim CEO and General Counsel. Exhibit 99.1. Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023. Financial Results and Corporate ...